1. Faithfull S, Brada M. Somnolence syndrome in adults following cranial irradiation for primary brain tumors. Clin Oncol 1998;10:250-254.
2. Marks JE, Baglan RJ, Prassad SC, et al. Cerebral radionecrosis: incidence and risk in relation to dose, time, fractionation and volume. Int J Radiat Oncol Biol Phys 1981;7:243-252.
3. Pezner RD, Archambeau JO. Brain tolerance unit: a method to estimate risk of radiation brain injury for various dose schedules. Int J Radiat Oncol Biol Phys 1981;7:397-402.
4. Leibel S, Sheline G. Tolerance of the brain and spinal cord to conventional irradiation. In: Gutin PH, Leibel SA, Sheline GE, eds. Radiation Injury to the Nervous System. New York: Raven; 1991:239-256.
6. Aristizabal S, Caldwell WL, Avila J. The relationship of time-dose fractionation factors to complications in the treatment of pituitary tumors by irradiation. Int J Radiat Oncol Biol Phys 1977;2:667-673.
7. Aristizabal S, Caldwell WL, Avila J, et al. Relationship of time dose factors to tumor control and complications in the treatment of Cushing's disease by irradiation. Int J Radiat Oncol Biol Phys 1977;2:47-54.
8. Harris JR, Levene MB. Visual complications following irradiation for pituitary adenomas and craniopharyngiomas. Radiology 1976;120:167-171.
10. Tishler RB, Loeffler JS, Lunsford D, et al. Tolerance of cranial nerves of the cavernous sinus to radiosurgery. Int J Radiat Oncol Biol Phys 1993;27:215-221.
11. Mitsumori M, Shrieve D, Alexander E, et al. Initial clinical results of LINAC-based ster-eotactic radiosurgery and stereotactic radiotherapy for pituitary adenomas. Int J Radiat Oncol Biol Phys 1998;42:573-580.
12. Perks JR, Jalali R, Cosgrove VP, et al. Optimization of stereotactically-guided conformal treatment planning of sellar and parasellar tumors, based on normal brain dose volume histograms. Int J Radiat Oncol Biol Phys 1999;45:507-513.
13. Jalali R, Brada M, Perks JR, et al. Stereotactic conformal radiotherapy for pituitary adenomas: technique and preliminary experience. Clin Endocrinol (Oxf) 2000;52: 695-702.
14. Khoo VS, Oldham M, Adams EJ, et al. Comparison of intensity-modulated tomotherapy with stereotactically guided conformal radiotherapy for brain tumors. Int J Radiat Oncol Biol Phys 1999;45:415-425.
15. Gittoes NJ, Bates AS, Tse W, et al. Radiotherapy for non-functioning pituitary tumours. Clin Endocrinol (Oxf) 1998;48:331-337.
16. Bradley KM, Adams CB, Potter CP, et al. An audit of selected patients with non-functioning pituitary adenoma treated by transsphenoidal surgery without irradiation. Clin Endocrinol (Oxf) 1994;41:655-659.
17. Lillehei KO, Kirschman DL, Kleinschmidt-DeMasters BK, et al. Reassessment of the role of radiation therapy in the treatment of endocrine-inactive pituitary macroadenomas. Neurosurgery 1998;43:432-438; discussion 438-439.
18. Brada M, Rajan B, Traish D, et al. The long-term efficacy of conservative surgery and radiotherapy in the control of pituitary adenomas. Clin Endocrinol (Oxf) 1993;38:571-578.
19. Grigsby PW, Simpson JR, Emami BN, et al. Prognostic factors and results of surgery and postoperative irradiation in the management of pituitary adenomas. Int J Radiat Oncol Biol Phys 1989;16:1411-1417.
20. McCollough W, Marcus RJ, Rhoton A, et al. Long-term follow up of radiotherapy for pituitary adenoma: the absence of late recurrence after 4500cGy. Int J Radiat Oncol Biol Phys 1991;21:607-614.
21. Davis DH, Laws ER, Jr, Ilstrup DM, et al. Results of surgical treatment for growth hormone-secreting pituitary adenomas. J Neurosurg 1993;79:70-75.
22. Freda PU, Wardlaw SL, Post KD. Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. J Neurosurg 1998;89:353-358.
23. Fahlbusch R, Honegger J, Buchfelder M. Surgical management of acromegaly. Endocrinol Metab Clin North Am 1992;21:669-692.
24. Biermasz NR, Dulken HV, Roelfsema F. Postoperative radiotherapy in acromegaly is effective in reducing GH concentration to safe levels. Clin Endocrinol (Oxf) 2000;53:321-327.
25. Ciccarelli E, Corsello SM, Plowman PN, et al. Prolonged lowering of growth hormone after radiotherapy in acromegalic patients followed for over 15 years. In: Landolt AAM, Heitz PU, Zapf J, et al., eds. Advances in Pituitary Adenoma Research. Pergamon Press; 1988:269-272.
26. Littley MD, Shalet SM, Swindell R, et al. Low-dose pituitary irradiation for acromegaly. Clin Endocrinol (Oxf) 1990;32:261-270.
27. Lawrence AM, Pinsky SM, Goldfine ID. Conventional radiation therapy in acromegaly. A review and reassessment. Arch Intern Med 1971;128:369-377.
28. Feek CM, McLelland J, Seth J, et al. How effective is external pituitary irradiation for growth hormone- secreting pituitary tumors? Clin Endocrinol (Oxf) 1984;20:401-408.
29. Howlett TA, Plowman PN, Wass JA, et al. Megavoltage pituitary irradiation in the management of Cushing's disease and Nelson's syndrome: long-term follow-up. Clin Endocrinol (Oxf) 1989;31:309-323.
30. Estrada J, Boronat M, Mielgo M, et al. The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease. N Engl J Med 1997;336:172-177.
31. Jenkins PJ, Trainer PJ, Plowman PN, et al. The long-term outcome after adrenalectomy and prophylactic pituitary radiotherapy in adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab 1995;80:165-171.
32. Mehta AE, Reyes FI, Faiman C. Primary radiotherapy of prolactinomas. Eight- to 15-year follow-up. Am J Med 1987;83:49-58.
33. Littley MD, Shalet SM, Reid H, et al. The effect of external pituitary irradiation on elevated serum prolactin levels in patients with pituitary macroadenomas. Q J Med 1991;81:985-998.
34. Bengtsson BA, Eden S, Ernest I, et al. Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand 1988;223:327-335.
35. Bates AS, Van't Hoff W, Jones JM, et al. An audit of outcome of treatment in acromegaly. Q J Med 1993;86:293-299.
36. Orme SM, McNally RJ, Cartwright RA, et al. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998;83:2730-2734.
38. Bulow B, Hagmar L, Mikoczy Z, et al. Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol 1997;46:75-81.
39. Bates AS, Van't Hoff W, Jones PJ, et al. The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab 1996;81:1169-1172.
40. Bates AS, Bullivant B, Sheppard MC, et al. Life expectancy following surgery for pituitary tumors. Clin Endocrinol (Oxf) 1999;50:315-319.
41. Nilsson B, Gustavasson-Kadaka E, Bengtsson BA, et al. Pituitary adenomas in Sweden between 1958 and 1991: incidence, survival, and mortality. J Clin Endocrinol Metab 2000;85:1420-1425.
42. Tomlinson JW, Holden N, Hills RK, et al. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 2001;357:425-431.
43. Brada M, Ford D, Ashley S, et al. Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma. Br Med J 1992;304:1343-1346.
44. Jones AE: Complications of radiotherapy for acromegaly. In: Wass JAH, ed. Treating Acromegaly. Bristol: 1996:115-125.
45. Beaney RP, Gibbs JSR, Brooks DJ, et al. Absence of irradiation induced ischaemic temporal lobe damage in patients with pituitary tumors. J Neuro-oncol 1987;5:129-137.
46. Grattan-Smith PJ, Morris JG, Langlands AO. Delayed radiation necrosis of the central nervous system in patients irradiated for pituitary tumors. J Neurol Neurosurg Psychiatry 1992;55:949-955.
47. Guinan EM, Lowy C, Stanhope N, et al. Cognitive effects of pituitary tumors and their treatments: two case studies and an investigation of 90 patients. J Neurol Neurosurg Psychiatry 1998;65:870-876.
48. Peace KA, Orme SM, Thompson AR, et al. Cognitive dysfunction in patients treated for pituitary tumors. J Clin Exp Neuropsychol 1997;19:1-6.
49. Littley MD, Shalet SM, Beardwell CG, et al. Hypopituitarism following external radiotherapy for pituitary tumors in adults. Q J Med 1989;70:145-160.
50. Littley MD, Shalet SM, Beardwell CG, et al. Radiation-induced hypopituitarism is dose-dependent. Clin Endocrinol (Oxf) 1989;31:363-373.
51. Tsang RW, Brierley JD, Panzarella T, et al. Role of radiation therapy in clinical hormonally-active pituitary adenomas. Radiother Oncol 1996;41:45-53.
52. Shalet SM. Cancer treatment and hypopituitarism. In: Sheaves R, Jenkins JS, Wass JAH, eds. Clinical Endocrine Oncology. Oxford: Blackwell Science; 1997:502-509.
53. Ron E, Modan B, Boice JD, Jr, et al. Tumors of the brain and nervous system after radiotherapy in childhood. N Engl J Med 1988;319:1033-1039.
54. Neglia JP, Meadows AT, Robinson LL, et al. Second neoplasms after acute lymphatic leukemia in childhood. N Engl J Med 1991;325:1330-1336.
55. Walter AW, Hancock ML, Pui CH, et al. Secondary brain tumors in children treated for acute lymphoblastic leukaemia at St Jude Children's Research Hospital. J Clin Oncol 1998;16:3761-3767.
56. Tsang RW, Laperriere NJ, Simpson WJ, et al. Glioma arising after radiation therapy for pituitary adenoma. A report of four patients and estimation of risk. Cancer 1993;72:2227-2233.
57. Jones A. Radiation oncogenesis in relation to the treatment of pituitary tumors. Clin Endocrinol (Oxf) 1991;35:379-397.
58. Brada M, Burchell L, Ashley S, et al. The incidence of cerebrovascular accidents in patients with pituitary adenoma. Int J Radiat Oncol Biol Phys 1999;45:693-698.
59. Milker-Zabel S, Debus J, Thilmann C, et al. Fractionated stereotactically guided radiotherapy and radiosurgery in the treatment of functional and nonfunctional adenomas of the pituitary gland. Int J Radiat Oncol Biol Phys 2001;50:1279-1286.
60. Thapar K, Kovacs K, Scheithauer BW, et al. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 1996;38:99-106; discussion 106-107.
61. Brada M, Ford D, Traish D, et al. Cerebrovascular mortality in patients with pituitary adenoma. Clin Endocrinol 2002;57:713-717.
Was this article helpful?
For centuries, ever since the legendary Ponce de Leon went searching for the elusive Fountain of Youth, people have been looking for ways to slow down the aging process. Medical science has made great strides in keeping people alive longer by preventing and curing disease, and helping people to live healthier lives. Average life expectancy keeps increasing, and most of us can look forward to the chance to live much longer lives than our ancestors.